Alvotech SA (ALVO)

Currency in USD
4.550
+0.180(+4.12%)
Closed·
4.5500.000(0.00%)
·
ALVO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.3454.670
52 wk Range
2.9406.530
Key Statistics
Prev. Close
4.55
Open
4.37
Day's Range
4.345-4.67
52 wk Range
2.94-6.53
Volume
1.56M
Average Volume (3m)
1.16M
1-Year Change
-13.0019%
Book Value / Share
-0.75
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALVO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.500
Upside
+64.84%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Alvotech SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.500
(+64.84% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy9.00+97.80%-New CoverageNov 10, 2026
Barclays
Buy8.00+75.82%4.00UpgradeSep 16, 2026
BofA Securities
Buy7.00+53.85%-New CoverageAug 24, 2026
Evercore ISI
Buy---New CoverageAug 14, 2026
UBS
Buy6.00+31.87%10.00MaintainMar 24, 2026

Alvotech SA SWOT Analysis


Biosimilar Pionee
Alvotech emerges as a potential top-3 global biosimilars pureplay, leveraging a unique B2B model in a competitive pharmaceutical landscape
Financial Trajectory
Despite current negative EPS, Alvotech projects strong growth with Q3 2024 revenue forecast at $93 million and positive EPS expected in the second fiscal yea
Product Portfolio
Explore Alvotech's key products Simlandi and Selardsi, alongside three upcoming BLA filings, driving the company's market expansion and revenue growth strategies
Market Valuation
Analysts maintain an $18 price target, reflecting confidence in Alvotech's long-term potential despite current profitability challenges and market uncertainties
Read full SWOT analysis

Alvotech SA Earnings Call Summary for Q3/2026

  • Alvotech posted Q3 revenue of $111.6M, missing estimates by 19.8%, with adjusted EPS loss of -$0.045 vs. forecast -$0.0186; shares fell 7.72%.
  • Product revenue surged 78% YoY to $58M and adjusted EBITDA jumped 40% sequentially to $31M, signaling operational recovery from manufacturing issues.
  • Full-year 2026 guidance maintained at $650M-$700M revenue and $180M-$220M EBITDA, but results expected at lower end of ranges; Q4 to be strongest ever.
  • Management projects substantial EBITDA growth in 2027 with positive Q4 cash flow; three biosimilar FDA decisions expected in December 2026.
  • Cash declined to $61M from $143M as working capital consumed $116M for manufacturing ramp-up; total debt stands at $1.56B amid litigation risks.
Last Updated: 12/11/2026, 16:12
Read Full Transcript

Earnings

Latest Release
Nov 11, 2026
EPS / Forecast
-0.04 / -0.02
Revenue / Forecast
111.6M / 139.22M
EPS Revisions
Last 90 days

ALVO Income Statement

Compare ALVO to Peers and Sector

Metrics to compare
ALVO
Peers
Sector
Relationship
P/E Ratio
−6.5x−1.7x−0.2x
PEG Ratio
0.01−0.150.00
Price/Book
−6.1x2.3x2.6x
Price / LTM Sales
3.3x3.8x2.7x
Upside (Analyst Target)
64.8%511.4%69.6%
Fair Value Upside
Unlock13.4%11.7%Unlock

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn’s disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
11.36M3.18%50.03M
Other Institutional Investors
246.24M68.99%1.08B
Public Companies & Retail Investors
99.32M27.83%437.49M
Total
356.91M100.00%1.57B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Celtic Holdings S.C.A.30.11%107,450,988473,322
Aztiq Pharma Partners S.à R.L.29.10%103,849,420457,457

People Also Watch

43.21
PENG
-1.41%
216.75
ALAB
+2.43%
122.94
CRDO
-0.81%
772.22
GEV
-0.99%
262.74
CEG
-1.99%

FAQ

What Is the Alvotech (ALVO) Stock Price Today?

The Alvotech stock price today is 4.550 USD.

What Stock Exchange Does Alvotech Trade On?

Alvotech is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Alvotech?

The stock symbol for Alvotech is "ALVO."

What Is the Alvotech Market Cap?

As of today, Alvotech market cap is 1.620B USD.

What Is Alvotech's Earnings Per Share (TTM)?

The Alvotech EPS (TTM) is -0.81.

When Is the Next Alvotech Earnings Date?

Alvotech will release its next earnings report on Mar 10, 2027.

From a Technical Analysis Perspective, Is ALVO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Alvotech Stock Split?

Alvotech has split 0 times.

How Many Employees Does Alvotech Have?

Alvotech has 1279 employees.

What is the current trading status of Alvotech (ALVO)?

As of Nov 19, 2026, Alvotech (ALVO) is trading at a price of 4.550 USD, with a previous close of 4.550 USD. The stock has fluctuated within a day range of 4.345 USD to 4.670 USD, while its 52-week range spans from 2.940 USD to 6.530 USD.

What Is Alvotech (ALVO) Price Target According to Analysts?

The average 12-month price target for Alvotech is 7.500 USD, with a high estimate of 9 USD and a low estimate of 4 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +64.84% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.